¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"chronic lupus erythematosus"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus tumidus
    ºñ´ë·çǪ½º, ºÎÀº·çǪ½º
  • lupus vulgaris
    º¸Åë·çǪ½º
  • anemia of chronic disease
    ¸¸¼ºº´ºóÇ÷
  • chronic
    ¸¸¼º-
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic active photosensitive dermatitis
    ¸¸¼ºÈ°¼º±¤¼±°ú¹ÎÇǺο°
  • chronic atrophic gastritis
    ¸¸¼ºÀ§ÃàÀ§¿°
  • chronic bronchitis
    ¸¸¼º±â°üÁö¿°
  • chronic exposure
    ¸¸¼º³ëÃâ
  • chronic fatigue syndrome
    ¸¸¼ºÇÇ·ÎÁõÈıº
  • chronic glomerulonephritis
    ¸¸¼ºÅ丮ÄáÆÏ¿°, ¸¸¼º»ç±¸Ã¼½Å¿°
  • chronic granulomatous disease
    ¸¸¼ºÀ°¾ÆÁ¾º´
  • chronic hepatitis
    ¸¸¼º°£¿°
  • chronic hypertrophic rhinitis
    ¸¸¼ººñÈÄÄÚ¿°, ¸¸¼ººñÈĺñ¿°
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • chronic myeloproliferative disorder
    ¸¸¼º°ñ¼öÁõ½ÄÁúȯ
  • chronic obstructive pulmonary disease
    ¸¸¼ºÆó¼âÆóÁúȯ, ¸¸¼ºÆó¼âÆóº´
  • chronic pain syndrome
    ¸¸¼ºÅëÁõÁõÈıº
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • chronic progressive disciform granulomatosis
    ¸¸¼ºÁøÇà¿ø¹ÝÀ°¾ÆÁ¾Áõ
  • chronic relapsing pancreatitis
    ¸¸¼ºÀç¹ßÀÌÀÚ¿°
  • chronic vasomotor instability
    ¸¸¼ºÇ÷°ü¿îµ¿ºÒ¾ÈÁ¤
  • lupus choroidopathy
    ·çÇÁ½º¸Æ¶ô¸·º´Áõ
  • discoid lupus
    ¿ø¹Ý¸ð¾ç·çǪ½º
  • exudative chronic discoid and lichenoid dermatitis
    »ïÃ⸸¼º¿ø¹Ýż±ÇǺο°
  • lupus hepatitis
    ·çǪ½º°£¿°
  • lupus
    ·çǪ½º, ³¶Ã¢
  • lupus miliaris desseminatus faciei
    ¹ü¹ß¾ó±¼Á¼½Ò·çǪ½º
  • lupus postexanthemicus
    ¹ßÁøÈÄ·çǪ½º
  • lupus tumidus
    ºñ´ë·çǪ½º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lupus erythematosus =le ³ª
    È«¹Ý¼º ·çǪ½º(ûõÚèàõ ¡­)
  • lupus erythematosus cell
    È«¹Ý¼º³¶Ã¢¼¼Æ÷
  • lupus erythematosus cell = LE cell
    È«¹Ý¼º ·çǪ½º¼¼Æ÷(¡­á¬øà)
  • lupus erythematosus disseminatus ³ª
    ÆÄÁ¾»ó(÷ëðúßÒ)È«¹Ý¼º ·çǪ½º.
  • lupus erythematosus factor = LE factor
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­)
  • lupus erythematosus factor =LE f.
    È«¹Ý¼º ·çǪ½ºÀÎÀÚ(ûõÚèàõ¡­ì×í­).
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾çÁõÈıº(ûõÚèàõ¡­åÆñøý¦ÏØ )
  • lupus erythematosus phenomenon = LE phenomenon
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ)
  • lupus erythematosus phenomenon =LE p.
    È«¹Ý¼º ·çǪ½ºÇö»ó(¡­úÞßÚ).
  • lupus erythematosus profundus
    ½ÉÀ缺 È«¹Ý¼º ·çǪ½º
  • lupus erythematosus test = LE test
    È«¹Ý¼º ·çǪ½º½ÃÇè(¡­ãËúÐ)
  • neonatal systemic lupus erythematosus
    ½Å»ý¾Æ Àü½Å¼º È«¹Ý¼º ·çǪ½º
  • sle= systemic lupus erythematosus
    Àü½Å¼º È«¹Ý¼º ·çǪ½º(îïãóàõ ûõÚèàõ¡­)
  • subacute cutaneous lupus erythematosus
    ¾Æ±Þ¼º ÇǺΠȫ¹Ý¼º ·çǪ½º
  • systemic lupus erythematosus
    Àü½Å¼ºÈ«¹Ý¼º·çÇÁ½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLE Systemic Lupus Erythematosus; Àü½Å¼º È«¹Ý¼º ·çǪ½º(³¶Ã¢)(îïãóàõ ûõÚèàõ)
DIL, Dil Dilantin; drug-induced lupus [erythematosus]
DILE drug-induced lupus erythematosus
LE lactate extraction; left ear; left eye; leukocyte elastase; leukoerythrogenic; live embryo; Long Eva...
LED light-emitting diode; lowest emitting dose; lupus erythematosus disseminatus
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
BILAG British Isles Lupus Assessment Group
DPLN Diffuse proliferative lupus nephritis
LAC Lupus AntiCoagulant
LA lupus anticoagulans
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lupus vulagris
    ½É»ó¼º ³¶Ã¢, ½É»ó¼º ·çǪ½º, º¸Åë ·çǪ½º
    ÇǺÎÀÇ ¿ø¹ß¼º °áÇÙÀ¸·Î ±«¾ç¼ºÀÇ ±¸Áø¼º ¼Ò°áÀýÀ» º¸ÀÌ¸ç Æ¯È÷ ¾ó±¼¿¡ Àß ¹ß»ýÇÑ´Ù.
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • chronic abscess
    ¸¸¼º ³ó¾ç
  • chronic acid
    Å©·Ò»ê
  • chronic acral dermatitis
    ¸¸¼º ¸»´Ü ÇǺο°
  • chronic actinic damage
    ¸¸¼º ±¤È­Çм± ¼Õ»ó
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic alveolar abscess
    ¸¸¼º Ä¡Á¶ ³ó¾ç
    Ä¡±Ù´Ü Ä¡Á¶°ñÀÌ Àå±â°£ µ¿¾È ³·Àº Á¤µµ·Î °¨¿°µÈ °Í.
  • chronic ambulatory peritoneal dialysis
    Áö¼Ó¼º ¿Ü·¡ º¹¸· Åõ¼®
  • chronic atrophic candidiasis
    ¸¸¼º À§Ã༺ ĵµð´ÙÁõ
    º¸Ã¶¹°°ú Á¢Ã˵Ǵ ºÎÀ§ÀÇ Á¡¸·ÀÌ ¸Å²öÇϰí À§ÃàÀÌ µÇ¸ç ¸íÈ®ÇÏ°Ô Àû»öÀ¸·Î µÇ´Â °ÍÀÌ Æ¯Â¡ÀÌ´Ù. ÀÌÈÄ¿¡ À̰ÍÀº ±Ù¿øÀÌ ´Ù¸¥ º¸Ã¶¹° ±¸³»¿°°ú º¸Ã¶¹°¿¡ ´ëÇÑ Á¢Ã˼º ¾Ë·¹¸£±â ¹ÝÀÀ°ú ±¸ºÐÇÏ¿©¾ß ÇÏ´Â À¯µÎ¼º ¼Ò°ßÀ» À¯¹ßÇÒ °¡´É¼ºÀÌ ÀÖ´Ù.
  • chronic atrophic laryngitis
    ¸¸¼º À§Ãà Èĵο°, ¸¸¼º À§Ã༺ Èĵο°
  • chronic bactrial prostatitis
    ¸¸¼º ¼¼±Õ¼º Àü¸³¼±¿°
  • chronic bullous dermatosis of childhood
    ¸¸¼º ¼Ò¾Æ ¼öÆ÷¼º ÇǺκ´
  • chronic carrier
    ¸¸¼º º¸±ÕÀÚ
  • chronic closed angle glaucoma
    ¸¸¼º Æó¼â°¢ ³ì³»Àå
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
pemphigus erythematosus An eruption involving sun-exposed skin, especially the face; the lesions are scaling erythematous macules and blebs, combining the clinical features of both lupus erythematosus and pemphigus vulgaris; bullae are subcorneal; probably a variant of pemphigus foliaceus.
Synonym: Senear-Usher disease, Senear-Usher syndrome.
(05 Mar 2000)
chilblain lupus Skin lesions seen in patients with lupus erythematosus, resembling the small, hardened nodular areas of a cold injury called chilblains.
Synonym: chilblain lupus.
(05 Mar 2000)
neonatal lupus Lupus erythematosus occurring in newborn children of mothers who had lupus during pregnancy; anti-SSA antibodies usually should be screened for; 50% have anti-nuclear antibodies. A variety of skin lesions are seen, which can resolve or leave scarring; the syndrome usually resolves; however cardiac manifestations can be fatal. Some children develop systemic lupus later in life.
(05 Mar 2000)
drug-induced lupus <dermatology> An inflammatory autoimmune disorder, similar to lupus, that develops in response to the use of a particular medication. It is characterised by anti-histone antibodies. More benign than the usual disease, with less renal involvement. The syndrome clears after stopping the offending drug.
Drugs that are known to cause this reaction include procainamide, isoniazid, sulphasalazine, hydralazine, methyldopa, phenytoin, chlorpromazine and penicillamine.
The arthritis, cardiac, pulmonary and systemic features may be present, but the kidney involvement (nephritis) and neurologic disease are rare.
Symptoms generally resolve spontaneously after stopping the medication. Complications include myocarditis, pericarditis, thrombocytopenic purpura and infections.
(18 Jul 2002)
lupus A systemic disease that results from an autoimmune mechanism. Individuals with lupus will produce antibodies to their own body tissues. The resultant inflammation can cause kidney damage, arthritis, pericarditis and vasculitis.
(27 Sep 1997)
lupus anticoagulant An immunoglobulin that interferes with blood coagulation and has antithromboplastin activity. This immunoglobulin can prolong blood clotting and occurs in approximately 25% of people with lupus.
(27 Sep 1997)
lupus anticoagulants Lupus anticoagulants are a common cause of a prolonged activated partial thromboplastin time (APTT) which is corrected by the addition of platelet -rich plasma (or phospholipids) and not by platelet-poor plasma. The methods of choice for detection of lupus anticoagulants are the kaolin clotting time using the rabbit brain neutralisation procedure and the dilute Russell viper venom test (dRVVT).
Current data suggest that lupus anticoagulants and antibodies to negatively charged phospholipids (cardiolipin, phosphatidylserine, phosphatidic acid and phosphatidylinositol) are risk factors for arterial and venous thrombosis and for recurrent abortions in populations of patients which are distinct but overlapping. Drug-induced lupus anticoagulants are also associated with increased risk of thrombosis. Current testing for lupus anticoagulants and phospholipid antibodies (cardiolipin plus phosphatidylserine) may be useful for assessing risk in patients with systemic lupus erythematosus. Some data indicate that lupus anticoagulants assays are more reliable predictors of thrombosis, foetal loss and thrombocytopenia than are cardiolipin antibody (ACA) assays. Although the technology is in many ways more reliable, the rush to describe associations of lupus anticoagulants with various disorders has been much less scientifically unseemly than has been that of ACAs with their bewildering variety of clinical associations. The contribution of one serious study must, it seems, render tolerable the excess of trivia recently published in this area.
See also cardiolipin antibodies and phospholipid antibodies.
(05 Mar 2000)
lupus band test A direct immunofluorescent technique for demonstrating a band of immunoglobulins at the dermal-epidermal junction of the skin of patients with lupus erythematosus.
(05 Mar 2000)
lupus coagulation inhibitor An antiphospholipid antibody found in association with systemic lupus erythematosus (lupus erythematosus, systemic), antiphospholipid syndrome, and in a variety of other diseases as well as in healthy individuals. In vitro, the antibody interferes with the conversion of prothrombin to thrombin and prolongs the partial thromboplastin time. In vivo, it exerts a procoagulant effect resulting in thrombosis mainly in the larger veins and arteries. It further causes obstetrical complications, including foetal death and spontaneous abortion, as well as a variety of haematologic and neurologic complications.
(12 Dec 1998)
lupus erythematodes Skin disease in which there are red scaly patches, especially over the nose and cheeks. May be a symptom of systemic lupus erythematosus.
(18 Nov 1997)
lupus glomerulonephritis-pathology Patient survival and preservation of renal function are predictable from renal pathology as demonstrated by biopsy and defined by the histological classification of the International Study of Kidney Disease in Children/World Health Organization (ISKDC/WHO). Semi-quantitative indices of nephron loss (chronicity index) and activity of acute potentially reversible inflammation (activity index) are not predictive of individual outcome, renal failure or death in patients with aggressively treated SLE GN.
(05 Mar 2000)
lupus-like syndrome <syndrome> A clinical syndrome resembling that of systemic lupus erythematosus, but due to some other cause.
(05 Mar 2000)
lupus livido Persistent cyanotic lesions on the extremities, associated with the cutaneous manifestations of Raynaud's disease.
(05 Mar 2000)
lupus lymphaticus A congenital nevoid lesion consisting of a circumscribed group of tense lymph vesicles.
Synonym: lupus lymphaticus, lymphangiectodes, lymphangioma capillare varicosum, lymphangioma superficium simplex.
(05 Mar 2000)
lupus miliaris disseminatus faciei A millet-like papular eruption of the face, associated with a (histopathologically) tuberculoid perifollicular infiltration, but probably related to rosacea rather than tuberculous infection.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á